Weight loss: Cornerstone in the treatment of non-alcoholic fatty liver disease

Minerva Gastroenterologica e Dietologica

Volumn 56, Issue 2, 2010, Pages 159-167

  Tilg, H ^a   Moschen, A ^a  

^a INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Liver diseases; Metabolic syndrome X; Weight loss

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; INSULIN; PIOGLITAZONE; RIMONABANT; SIBUTRAMINE; TETRAHYDROLIPSTATIN;

BARIATRIC SURGERY; CLINICAL FEATURE; DIET THERAPY; DISEASE SEVERITY; ECHOGRAPHY; EXERCISE; GROUPS BY AGE; HEART INFARCTION; HUMAN; INSULIN RESISTANCE; LIFESTYLE MODIFICATION; LIVER BIOPSY; LIVER FUNCTION TEST; LIVER HISTOLOGY; MENTAL DISEASE; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OBESITY; PHENOTYPE; REVIEW; STROKE; THERAPY EFFECT; TREATMENT OUTCOME; WEIGHT REDUCTION;

BODY MASS INDEX; CHRONIC DISEASE; DIET, REDUCING; FATTY LIVER; FATTY LIVER, ALCOHOLIC; HUMANS; LIFE STYLE; METABOLIC SYNDROME X; OBESITY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS; TREATMENT OUTCOME; WEIGHT LOSS;

EID: 77954748222     PISSN: 00264776     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001;50:1844-50. (Pubitemid 33641605)
2. Bedogni G, Miglioli L, Masutti F, Tiribelli C, Marchesini G, Bellentani S. Prevalence of and risk factors for non-alcoholic fatty liver disease: the Dionysos nutrition and liver study. Hepatology 2005;42:44-52. (Pubitemid 40911310)
3. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002;346:1221-31.
4. Fassio E, Alvarez E, Dominguez N, Landeira G, Longo C. Natural history of nonalcoholic steatohepatitis: a longitudinal study of repeat liver biopsies. Hepatology 2004;40:820-6. (Pubitemid 39288114)
5. Adams LA, Lymp JF, St Sauver J, Sanderson SO, Lindor KD, Feldstein A et al. The natural history of nonalcoholic fatty liver disease: a population-based cohort study. Gastroenterology 2005;129:113-21. (Pubitemid 41002048)
6. Tilg H, Moschen AR. Insulin resistance, inflammation, and non-alcoholic fatty liver disease. Trends Endocrinol Metab 2008;19:371-9.
7. Bugianesi E, Gentilcore E, Manini R, Natale S, Vanni E, Villanova N et al. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am J Gastroenterol 2005;100:1082-90. (Pubitemid 40769045)
8. Aithal GP, Thomas JA, Kaye PV, Lawson A, Ryder SD, Spendlove I et al. Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis. Gastroenterology 2008;135:1176-84.
9. Sanyal AJ. A randomized controlled trial of Pioglitazone or vitamin E for nonalcoholic steatohepatitis (PIVENS). AASLD 2009;Abstract LB2:
10. Harrison SA, Day CP. Benefits of lifestyle modification in NAFLD. Gut 2007;56:1760-9.
11. Marchesini G, Suppini A, Forlani G. NAFLD treatment: cognitive-behavioral therapy has entered the arena. J Hepatol 2005;43:926-8. (Pubitemid 41627975)
12. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346:393-403. (Pubitemid 34437694)
13. Lindstrom J, Ilanne-Parikka P, Peltonen M, Aunola S, Eriksson JG, Hemio K et al. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish Diabetes Prevention Study. Lancet 2006;368:1673-9.
14. Neuschwander-Tetri BA, Brunt EM, Wehmeier KR, Oliver D, Bacon BR. Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology 2003;38:1008-17. (Pubitemid 37221684)
15. Saadeh S, Younossi ZM, Remer EM, Gramlich T, Ong JP, Hurley M et al. The utility of radiological imaging in nonalcoholic fatty liver disease. Gastroenterology 2002;123:745-50. (Pubitemid 34977081)
16. Angulo P. Noninvasive assessment of fibrosis and steatosis in NASH and ASH. Gastroenterol Clin Biol 2009;33:940-8.
17. Andersen T, Gluud C, Franzmann MB, Christoffersen P. Hepatic effects of dietary weight loss in morbidly obese subjects. J Hepatol 1991;12:224-9.
18. Luyckx FH, Desaive C, Thiry A, Dewe W, Scheen AJ, Gielen JE et al. Liver abnormalities in severely obese subjects: effect of drastic weight loss after gastroplasty. Int J Obes Relat Metab Disord 1998;22:222-6.
19. Wang RT, Koretz RL, Yee HF, Jr. Is weight reduction an effective therapy for nonalcoholic fatty liver? A systematic review. Am J Med 2003;115:554-9.
20. Park HS, Kim MW, Shin ES. Effect of weight control on hepatic abnormalities in obese patients with fatty liver. J Korean Med Sci 1995;10:414-21.
21. Ueno T, Sugawara H, Sujaku K, Hashimoto O, Tsuji R, Tamaki S et al. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol 1997;27:103-7. (Pubitemid 27357062)
22. Ranlov I, Hardt F. Regression of liver steatosis following gastroplasty or gastric bypass for morbid obesity. Digestion 1990;47:208-14.
23. Huang MA, Greenson JK, Chao C, Anderson L, Peterman D, Jacobson J et al. One-year intense nutritional counseling results in histological improvement in patients with non-alcoholic steatohepatitis: a pilot study. Am J Gastroenterol 2005;100:1072-81. (Pubitemid 40769044)
24. Gill HK, Wu GY. Non-alcoholic fatty liver disease and the metabolic syndrome: effects of weight loss and a review of popular diets. Are low carbohydrate diets the answer? World J Gastroenterol 2006;12:345-53.
25. Promrat K, Kleiner DE, Niemeier HM, Jackvony E, Kearns M, Wands JR et al. Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis. Hepatology 2010;51:121-9.
26. Mathurin P, Hollebecque A, Arnalsteen L, Buob D, Leteurtre E, Caiazzo R et al. Prospective study of the long-term effects of bariatric surgery on liver injury in patients without advanced disease. Gastroenterology 2009;137:532-40.
27. Bellentani S, Dalle GR, Suppini A, Marchesini G. Behavior therapy for nonalcoholic fatty liver disease: The need for a multidisciplinary approach. Hepatology 2008;47:746-54.
28. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005;41:1313-21.
29. St George A, Bauman A, Johnston A, Farrell G, Chey T, George J. Independent effects of physical activity in patients with nonalcoholic fatty liver disease. Hepatology 2009;50:68-76.
30. Maggard MA, Shugarman LR, Suttorp M, Maglione M, Sugerman HJ, Livingston EH et al. Meta-analysis: surgical treatment of obesity. Ann Intern Med 2005; 142:547-59.
31. Sjostrom L, Narbro K, Sjostrom CD, Karason K, Larsson B, Wedel H et al. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med 2007;357:741-52.
32. Moschen AR, Molnar C, Wolf AM, Weiss H, Graziadei I, Kaser S et al. Effects of weight loss induced by bariatric surgery on hepatic adipocytokine expression. J Hepatol 2009;51:765-77.
33. Dixon JB, Bhathal PS, Hughes NR, O'Brien PE. Nonalcoholic fatty liver disease: Improvement in liver histological analysis with weight loss. Hepatology 2004;39:1647-54.
34. Mattar SG, Velcu LM, Rabinovitz M, Demetris AJ, Krasinskas AM, Barinas-Mitchell E et al. Surgically-induced weight loss significantly improves nonalcoholic fatty liver disease and the metabolic syndrome. Ann Surg 2005;242:610-7.
35. Liu X, Lazenby AJ, Clements RH, Jhala N, Abrams GA. Resolution of nonalcoholic steatohepatits after gastric bypass surgery. Obes Surg 2007;17:486-92. (Pubitemid 46850188)
36. Mummadi RR, Kasturi KS, Chennareddygari S, Sood GK. Effect of bariatric surgery on nonalcoholic fatty liver disease: systematic review and meta-analysis. Clin Gastroenterol Hepatol 2008;6:1396-402.
37. Chavez-Tapia NC, Tellez-Avila FI, Barrientos-Gutierrez T, Mendez-Sanchez N, Lizardi-Cervera J, Uribe M. Bariatric surgery for non-alcoholic steatohepatitis in obese patients. Cochrane Database Syst Rev 2010;CD007340.
38. Kral JG, Thung SN, Biron S, Hould FS, Lebel S, Marceau S et al. Effects of surgical treatment of the metabolic syndrome on liver fibrosis and cirrhosis. Surgery 2004;135:48-58. (Pubitemid 38041453)
39. Baltasar A, Serra C, Perez N, Bou R, Bengochea M. Clinical hepatic impairment after the duodenal switch. Obes Surg 2004;14:77-83. (Pubitemid 38130720)
40. Harrison SA, Ramrakhiani S, Brunt EM, Anbari MA, Cortese C, Bacon BR. Orlistat in the treatment of NASH: a case series. Am J Gastroenterol 2003;98:926-30. (Pubitemid 36576325)
41. Harrison SA, Fincke C, Helinski D, Torgerson S, Hayashi P. A pilot study of orlistat treatment in obese, non-alcoholic steatohepatitis patients. Aliment Pharmacol Ther 2004;20:623-8. (Pubitemid 39279050)
42. Zelber-Sagi S, Kessler A, Brazowsky E, Webb M, Lurie Y, Santo M et al. A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2006;4:639-44.
43. Harrison SA, Fecht W, Brunt EM, Neuschwander-Tetri BA. Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trial. Hepatology 2009;49:80-6.
44. Sabuncu T, Nazligul Y, Karaoglanoglu M, Ucar E, Kilic FB. The effects of sibutramine and orlistat on the ultrasonographic findings, insulin resistance and liver enzyme levels in obese patients with non-alcoholic steatohepatitis. Rom J Gastroenterol 2003;12:189-92. (Pubitemid 37152602)
45. Van Gaal LF, Rissanen AM, Scheen AJ, Ziegler O, Rossner S. Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005;365:1389-97.
46. Rucker D, Padwal R, Li SK, Curioni C, Lau DC. Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ 2007;335:1194-9. (Pubitemid 350273303)
47. Hickman IJ, Clouston AD, Macdonald GA, Purdie DM, Prins JB, Ash S et al. Effect of weight reduction on liver histology and biochemistry in patients with chronic hepatitis C. Gut 2002;51:89-94. (Pubitemid 34717750)
48. Hickman IJ, Jonsson JR, Prins JB, Ash S, Purdie DM, Clouston AD et al. Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life. Gut 2004;53:413-9. (Pubitemid 38241340)
49. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults - The Evidence Report. National Institutes of Health. Obes Res 1998;6 Suppl 2:51S-209S.
50. th ed. Washington, DC: U.S. Government Printing Office; 2005.